Glowing dye could replace radioactive tracers in breast cancer surgery

NCT ID NCT07311278

Ongoing Diagnosis Sponsor: St. Antonius Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a fluorescent dye called indocyanine green (ICG) can replace the current radioactive tracer (technetium) for finding sentinel lymph nodes in breast cancer patients. About 493 women with early-stage breast cancer will take part. Surgeons will first use the standard method, then learn to use ICG, comparing how well each method finds the lymph nodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Indocyanine green (ICG) dye
What this could lead to: If successful, this could make sentinel lymph node detection safer and more accessible by replacing radioactive tracers with a fluorescent dye.
What could go wrong: This is an implementation study, not a test of effectiveness. ICG may not work as well as technetium in all patients, and results may vary across hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Antoni van Leeuwenhoek Ziekenhuis

Amsterdam, Netherlands
Bernhoven Ziekenhuis

Uden, Netherlands
Erasmus Medisch Centrum

Rotterdam, Netherlands
FlevoZiekenhuis

Almere Stad, Netherlands
HagaZiekenhuis

The Hague, Netherlands
Isala Ziekenhuis

Zwolle, Netherlands
Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands
Maastricht Universitair Medisch Centrum

Maastricht, Netherlands
Ospedale Pederzoli

Peschiera del Garda, Italy
Reinier de Graaf Gasthuis

Delft, Netherlands
Van Weel-Bethesda Ziekenhuis

Dirksland, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.